At a 20% prevalence of high-grade prostate cancer (as seen in the validation cohort), the MTT is 229.5 and 122.0 for MPS2 + versus s7MPS2 + and MPS2 versus s7MPS2, respectively. The gene discussed is IDS; the disease is prostate carcinoma.